Travere Therapeutics (TVTX) FDA Review Extended to April 13
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2026
0mins
Source: Yahoo Finance
- FDA Review Extension: Travere Therapeutics' FILSPARI drug's supplemental New Drug Application review period has been extended to April 13, indicating a positive overall approval outlook despite the delay, as deeper evaluation of clinical data is expected to aid in approval.
- Price Target Adjustment: Bank of America lowered its price target for Travere from $47 to $43 while maintaining a 'Buy' rating, reflecting confidence in the company's future growth despite facing short-term challenges.
- Clinical Data Supplement: The FDA requested additional data from Travere to further define the clinical benefits of FILSPARI, classifying this submission as a Major Amendment to the sNDA, which necessitated a three-month extension, highlighting the agency's recognition of the drug's potential.
- Market Outlook: If approved, FILSPARI would become the first medication specifically indicated for FSGS, potentially capturing significant market share in the rare kidney disease treatment sector, thereby driving Travere's revenue growth.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like TVTX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 42.89 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 30.280
Low
31.00
Averages
42.89
High
49.00
Current: 30.280
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Robbins Geller Investigates Potential Securities Violations by Travere Therapeutics
- Investigation Launched: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics (NASDAQ: TVTX), focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Loss Focus: The investigation particularly targets investors who suffered losses in Travere, with the firm encouraging affected individuals to provide information, demonstrating a commitment to protecting investor rights.
- Law Firm Strength: Robbins Geller is recognized as one of the world's leading law firms in securities fraud and shareholder litigation, having ranked #1 in ISS Securities Class Action Services for four out of the last five years, highlighting its strong capability in securing investor compensation.
- Historical Recovery Record: In 2024, the firm recovered over $2.5 billion for investors in securities-related class action cases, surpassing the combined total of the next five law firms, showcasing its exceptional performance in the securities litigation arena.
Continue Reading
Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Market Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing robust market demand for its products.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, driving total revenue up from $62.9 million to $164.9 million, highlighting its strong performance in the rare disease treatment sector.
- FDA Review Catalyst: The ongoing FDA review of Travere's FILSPARI for potential use in treating focal segmental glomerulosclerosis has heightened market expectations for the company, further bolstering Palisades' investment confidence.
Continue Reading